BioInvent is a clinical-stage biotechnology company focused on discovering and developing antibody-based cancer therapies. Drawing on expertise in immunology, cancer biology and antibody biology, it develops immuno-oncology candidates intended to improve cancer treatment and benefit patients. Its clinical pipeline includes programs such as BI-1808 for T-cell lymphoma and solid tumors, BI-1206 for non-Hodgkin lymphoma and solid tumors, and BT-001 for solid tumors.

The company’s discovery and development work is supported by F.I.R.S.T., a proprietary platform that uses patient material to identify clinically relevant disease targets and matching antibodies. BioInvent also uses its n-CoDeR antibody library, which contains antibodies designed to bind specifically and strongly to their targets. Alongside its therapeutic research, BioInvent offers contract manufacturing through BioInvent Manufacturing, producing drug substance for clinical trials using in-house GMP facilities and single-use technology. The company also works with industry partners through ongoing collaborations. Its activities span antibody discovery, preclinical research, clinical development and manufacturing, with a focus on advancing potential cancer immunotherapies.